Tx 60 yo w/ liver mets, questionable resectablility, 18 mo after adj FOLFOX?
What treatment approach would you most likely recommend for a 60-year-old patient with KRAS wt colon cancer who presents 18 months after adjuvant FOLFOX with 4 bilateral liver lesions that are questionable in terms of resectability but may be operable if a response is achieved?
Bendell JC et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: Results from ARIES, a bevacizumab observational cohort study. Oncologist 2012;17(12):1486-95. Abstract
Fuchs CS et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study. J Clin Oncol 2008;26(4):689-90. Abstract
Giantonio BJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 2007;25(12):1539-44. Abstract
Heinemann V et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). Proc ASCO 2013;Abstract LBA3506.
Loupakis F et al. FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. Gastrointestinal Cancers Symposium 2013;Abstract 336.
Primrose JN et al. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. Proc ASCO 2013;Abstract 3504.
Saltz LB et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26(12):2013-9. Abstract